Melatonin Stem Cell Carrier for Intestinal Epithelium Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory bowel disease, such as ulcerative colitis and Crohn's disease, face challenges with refractoriness, resistance, and side effects, and are limited in restoring the integrity of the intestinal mucosa and regenerating tissue.
Innovation Solution
A stem cell-drug carrier, known as heterospheroids, is developed by mixing melatonin microspheres with 3D mesenchymal stem cells, which continuously release melatonin and PGE2, inducing revival stem cells to regenerate intestinal epithelial cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current drugs are used to treat inflammatory bowel disease, then some therapeutic effect is achieved, but refractoriness, resistance, and side effects occur, and tissue regeneration is limited
Solution Approach 1:
The patent combines stem cells with drug carriers containing melatonin and PGE2 to create a composite therapeutic system. This composite approach allows simultaneous delivery of multiple therapeutic agents (stem cells for tissue regeneration, melatonin for antioxidant effects, PGE2 for stem cell induction) that work synergistically to treat IBD while reducing dependence on conventional drugs that cause resistance and side effects
Solution Approach 2:
The drug carrier acts as an intermediary system that delivers both stem cells and pharmaceutical compounds (melatonin and PGE2) to the target site. This intermediary delivery system enables coordinated release of multiple therapeutic agents, enhancing treatment effectiveness while minimizing harmful effects through controlled delivery rather than direct drug administration
2Productivity
If stem cells are used to regenerate intestinal epithelium, then tissue regeneration is promoted, but stem cells are easily lost by signals such as DSS and radiation exposure
Solution Approach 1:
The patent pre-protects stem cells by encapsulating them within a drug carrier shell containing melatonin and PGE2 before exposing them to harmful environments. The melatonin provides antioxidant protection against oxidative stress from radiation and DSS, while the carrier structure physically protects stem cells from direct exposure to damaging signals, enabling them to survive and function in inflamed intestinal environments
Solution Approach 2:
The stem cell-drug carrier composite system combines protective pharmaceutical agents (melatonin for antioxidant protection, PGE2 for stem cell induction and survival signaling) with the stem cells themselves. This composite structure enhances stem cell survival by providing both chemical protection against oxidative stress and biological signals that promote stem cell maintenance and differentiation
3Productivity
If revival stem cells are induced by PGE2, then epithelial tissue regeneration is enhanced, but the treatment requires precise control of PGE2 release to avoid side effects
Solution Approach 1:
The patent merges multiple therapeutic functions into a single integrated drug carrier system. The carrier simultaneously delivers stem cells, melatonin, and PGE2, combining tissue protection, stem cell induction, and anti-inflammatory effects in one formulation. This merging eliminates the need for separate controlled delivery systems for each agent, reducing overall system complexity while maintaining precise local control at the target site
Solution Approach 2:
The drug carrier is designed as a multi-functional platform that performs multiple therapeutic roles: protecting stem cells from oxidative stress (melatonin function), inducing revival stem cells (PGE2 function), providing structural support, and enabling controlled local delivery. This universal carrier design eliminates the need for multiple separate delivery systems, simplifying the overall treatment approach while achieving precise control through localized single-dose administration
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The stem cell-drug carrier effectively induces revival stem cells, improving intestinal epithelial regeneration and reducing inflammation, thus treating intestinal damage diseases and inflammatory bowel disease.
Implementation Method 1
the stem cell-drug carrier continuously released melatonin and PGE2
Data Source
AI summary
The present disclosure relates to a stem cell-drug carrier including a melatonin-containing drug carrier and a stem cell, and more particularly, to a use of the stem cell for the treatment of intestinal epithelial damage disease and inflammatory bowel disease. According to the present disclosure, it was confirmed that the stem cell-drug carrier continuously released PGE2 and had excellent revival stem cell induction ability. This means that the stem cell-drug carrier of the present disclosure has an excellent intestinal epithelium regeneration effect, and the stem cell-drug carrier of the present disclosure can be used in various fields of treatment of intestinal damage disease and inflammatory bowel disease.